Intranasal naloxone administration for treatment of opioid overdose

American Journal of Health-System Pharmacy

Volumn 71, Issue 24, 2014, Pages 2129-2135

  Robinson, Amanda ^a   Wermeling, Daniel P ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; NALORPHINE; NALOXONE; NARCOTIC ANTAGONIST; OPIATE; NARCOTIC AGENT;

AGITATION; ARTICLE; DRUG ABSORPTION; DRUG COST; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG INTOXICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; HEADACHE; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; NAUSEA; NOSE MUCOSA; PARAMEDICAL PERSONNEL; RESPIRATION DEPRESSION; RISK ASSESSMENT; SEIZURE; TREMOR; VASCULARIZATION; VOMITING; WITHDRAWAL SYNDROME; ADVERSE EFFECTS; COMPLICATION; DRUG OVERDOSE; INTRAMUSCULAR DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; NEEDLESTICK INJURIES; OCCUPATIONAL INJURIES; RESCUE PERSONNEL;

ADMINISTRATION, INTRANASAL; DRUG OVERDOSE; EMERGENCY MEDICAL TECHNICIANS; HUMANS; INJECTIONS, INTRAMUSCULAR; NALOXONE; NARCOTIC ANTAGONISTS; NARCOTICS; NEEDLESTICK INJURIES; OCCUPATIONAL INJURIES;

EID: 84915756325     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp130798     Document Type: Article

References (45)

1. Warner M, Chen L, Makuc D. NCHS data brief: increase in fatal poisonings involving opioid analgesics in the United States, 1999-2006 (September 2009). www. cdc.gov/nchs/data/databriefs/db22.htm (accessed 2013 Sep 3)
2. Warner M, Chen LH, Makuc DM et al. NCHS data brief: drug poisoning deaths in the United States, 1980-2008 (December 2011). www.cdc.gov/nchs/ data/databriefs/db81.pdf (accessed 2013 Sep 3)
3. Centers for Disease Control and Prevention. QuickStats: number of deaths from poisoning, drug poisoning, and drug poisoning involving opioid analgesics- United States, 1999-2010. MMWR Morb Mortal Wkly Rep. 2013; 62:234
4. Substance Abuse and Mental Health Services Administration. Results from the 2009 National Survey on Drug Use and Health: volume I: summary of national findings (September 2010). www. samhsa.gov/data/2k9/2k9Resultsweb/ web/2k9results.pdf (accessed 2013 Sep 3)
5. Substance Abuse and Mental Health Services Administration. The DAWN report: highlights of the 2009 Drug Abuse Warning Network (DAWN) findings on drugrelated emergency department visits (December 28, 2010). http://oas.samhsa. gov/2k10/DAWN034/EDHighlights.htm (accessed 2013 Sep 3)
6. Boyer EW. Management of opioid analgesic overdose. N Engl J Med. 2012; 367:146-55
7. Hospira, Inc. Naloxone hydrochloride injection prescribing information (revised November 2006). http://dailymed.nlm. nih.gov/dailymed/archives/fdaDrugInfo. cfm?archiveid=2668 (accessed 2013 Sep 3)
8. McDermott C, Niamh CC. Prehospital medication administration: a randomised study comparing intranasal and intravenous routes. Emerg Med Int. 2012; 2012:476161
9. Greenberg MI, Roberts JR, Baskin SI. Endotracheal naloxone reversal of morphine-induced respiratory depression in rabbits. Ann Emerg Med. 1980; 9:289-92
10. Kristensen BB, Mikkelsen SS. [Pharmacological routes of administration in circulatory collapse.] Ugeskr Laeger. 1995; 157:6864-8. In Danish
11. Marcus R, Srivastava PU, Bell DM et al. Occupational blood contact among prehospital providers. Ann Emerg Med. 1995; 25:776-9
12. Barton ED, Ramos J, Colwell C et al. Intranasal administration of naloxone by paramedics. Prehosp Emerg Care. 2002; 6:54-8
13. Kerr D, Dietze P, Kelly AM. Intranasal naloxone for the treatment of suspected heroin overdose. Addiction. 2008; 103:379-86
14. Office of Emergency Medical Services, County of Sacramento. Intranasal medication administration. www.dhhs. saccounty.net/PRI/EMS/Documents/ PoliciesProceduresProtocols/8800/ PP-8831.02-Intranasal%20Medication% 20Administration.pdf (accessed 2013 Oct 20)
15. Office of Emergency Medical Services, State of Tennessee. Tennessee emergency medical services protocol guidelines (revised March 2014). http://health.state. tn.us/ems/PDF/Protocols.pdf (accessed 2013 Oct 20).
16. Maine Emergency Medical Services. Maine EMS: Prehospital treatment protocols, (effective December 1, 2013). www.maine.gov/ems/documents/2013-Maine-EMS-Protocols.pdf
17. Regional Emergency Medical Services Council of New York City, Inc. ALS protocol: 511-Altered mental status intranasal Narcan (naloxone) (July 18, 2006). www.nycremsco.org/images/articlesserver/2006-06%20ALS%20Protocol%20511%20-%20Altered%20Mental%20Status%20-%20Addition%20of%20Intra%20Nasal%20Narcan.pdf (accessed 2013 Oct 20).
18. Iijima I, Minamikawa J, Jacobson AE et al. Studies in the (+)-morphinan series. 5. Synthesis and biological properties of (+)-naloxone. J Med Chem. 1978; 21:398-400.
19. Hasbrouck JD. The antagonism of morphine anesthesia by naloxone. Anesth Analg. 1971; 50:954-9
20. Jasinski DR, Martin WR, Haertzen CA. The human pharmacology and abuse potential of N-Allylnoroxymorphone (naloxone). J Pharmacol Exp Ther. 1967; 157:420-6
21. Bennie RE, Boehringer LA, Dierdorf SF et al. Transnasal butorphanol is effective for postoperative pain relief in children undergoing myringotomy. Anesthesiology. 1998; 89:385-90
22. Committee on Drugs, American Academy of Pediatrics. Alternative routes of drug administration-Advantages and disadvantages [subject review]. Pediatrics. 1997; 100:143-52.
23. Evans JM, Hogg MI, Lunn JN et al. Degree and duration of reversal by naloxone of effects of morphine in conscious subjects. Br Med J. 1974; 2:589-91
24. Loimer N, Hofmann P, Chaudhry HR. Nasal administration of naloxone is as effective as the i.v. route in opiate addicts. Int J Addict. 1994; 29:819-27
25. Dowling J, Isbister GK, Kirkpatrick CM et al. Population pharmacokinetics of i.v., intramuscular, and intranasal naloxone in human volunteers. Ther Drug Monit. 2008; 30:490-6
26. Wermeling DP. A response to the opioid overdose epidemic: naloxone nasal spray. Drug Deliv Transl Res. 2013; 3:63-74
27. Hussain AA, Kimura R, Huang CH. Nasal absorption of naloxone and buprenorphine in rats. Int J Pharmacol. 1984; 21:233-7
28. Wolfe TR, Bernstone T. Intranasal drug delivery: an alternative to i.v. administration in selected emergency cases. J Emerg Nurs. 2004; 30:141-7
29. Naloxone [monograph]. In: Lexi-Drugs Online [online database]. Hudson, OH: Lexi-Comp (accessed 2013 Sep 30)
30. Kelly AM, Kerr D, Dietze P et al. Randomised trial of intranasal versus intramuscular naloxone in prehospital treatment for suspected opioid overdoses. Med J Aust. 2005; 182:24-7
31. Kerr D, Kelly AM, Dietze P et al. Randomized controlled trial comparing the effectiveness and safety of intranasal and intramuscular naloxone for the treatment of suspected heroin overdose. Addiction. 2009; 104:2067-74
32. Doe-Simkins M, Walley AY, Epstein A et al. Saved by the nose: bystanderadministered intranasal naloxone hydrochloride for opioid overdose. Am J Public Health. 2009; 99:788-91
33. Prescribe to Prevent: Prescribe naloxone, save a life. http://prescribetoprevent.org/ (accessed 2013 Sep 3)
34. Ohio Department of Health. Project DAWN (Deaths Avoided with Naloxone). www. healthy.ohio.gov/vipp/drug/ProjectDAWN. aspx (accessed 2013 Sep 3)
35. Robertson TM, Hendey GW, Stroh G, Shalit M. Intranasal naloxone is a viable alternative to i.v. naloxone for prehospital narcotic overdose. Prehosp Emerg Care. 2009; 13:512-5
36. Barton ED, Colwell CB, Wolfe T et al. Efficacy of intranasal naloxone as a needleless alternative for treatment of opioid overdose in the prehospital setting. J Emerg Med. 2005; 29:265-71
37. Merlin MA, Saybolt M, Kapitanyan R et al. Intranasal naloxone delivery is an alternative to i.v. naloxone for opioid overdoses. Am J Emerg Med. 2010; 28:296-303
38. Heard C, Creighton P, Lerman J. Intranasal flumazenil and naloxone to reverse over-sedation in a child undergoing dental restorations. Paediatr Anaesth. 2009; 19:795-7
39. Kelly AM, Koutsogiannis Z. Intranasal naloxone for life threatening opioid toxicity. Emerg Med J. 2002; 19:375
40. Ashton H, Hassan Z. Best evidence topic report. Intranasal naloxone in suspected opioid overdose. Emerg Med J. 2006; 23:221-3
41. National Institute on Drug Abuse Research report series. Cocaine: abuse and addiction. Washington, DC: Department of Health and Human Services; 1999 (revised, 2010 Sep). NIH publication no. 10-4166.
42. Foldes FF, Duncalf D, Kuwabara S. The respiratory, circulatory, and narcotic antagonistic effects of nalorphine, levallorphan, and naloxone in anaesthetized subjects. Can Anaesth Soc J. 1969; 16:151-61
43. Linder C, Fishman J. Narcotic antagonists. 1. Isomeric sulfate and acetate esters of naloxone (N-Allylnoroxymorphone). J Med Chem. 1973; 16:553-6.
44. Business Wire. Naloxone nasal spray on development fast track as emergency treatment for opioid overdose (September 20, 2013). www.businesswire. com/news/home/20130920005500/en/ Naloxone-Nasal-Spray-Development- Fast-Track-Emergency (accessed 2013 Nov 12)
45. AntiOp, Inc. AntiOp: about us. http:// antiop.net/about-us.html (accessed 2013 Nov 12)